ESTRO 2023 | Evolution of fractionation regimens in breast cancer radiotherapy: SKAGEN Trial 1 and HypoG-01 Trial

Sofia Rivera, MD, PhD, Gustave Roussy, Villejuif, France, discusses the evolution of fractionation regimens in breast radiotherapy and the need for evidence regarding hypofractionated radiotherapy for local regional irradiation, specifically involving lymph nodes. Dr Rivera highlights that although there were reassuring results from retrospective and prospective cohorts and subgroups of trials, no specific trial had been conducted to address this question before the SKAGEN Trial 1 trial (NCT02384733) and the Phase III HypoG-01 trial (NCT03127995) of locoregional hypo vs normo fractionated radiotherapy in early breast cancer. These two trials were designed to provide level one evidence on hypofractionated radiotherapy including lymph nodes. Concerns regarding increased exposure of normal tissues, such as lung and heart tissue, were taken into consideration. The first results of the SKAGEN Trial 1 were presented the previous year, and at this year’s ESTRO the initial results of the HypoG-01 trial were presented. This interview took place at the ESTRO congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.